Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 147

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 9C
Chunk 147
---
%
  
    Michelle Yanez 
     24,391  
     * 
  
    Matthew Whalen 
     12,500  
     * 
  
    Matthew Del Giudice 
     12,500  
     * 
  
    Edward MacPherson 
     12,500  
     * 
  
    Craig Eagle 
     487,805  
     1.64%

    All current directors and
    officers as a group (6 persons) 
     1,559,381  
     5.13%

    5% Stockholders 

    Brian McNulty(1) 
     10,949,152  
     34.11%

    *Represents beneficial ownership of less than
    1% 

    (1)
    Includes
    (i) 5,406,431 shares held by the Bay Shore Trust, (ii) 1,853,659 shares held by the Celeste J. Williams Lifetime QTIP Trust, (iii)
    24,391 shares held directly by Mr. McNulty, (iv) 1,325,646 shared held by Miralogx LLC in which Bay Shore Trust is the beneficial
    owner and (v) 2,339,025 shares issuable pursuant to a warrant held by the Bay Shore Trust that is immediately exercisable. As trustee
    for both the Bay Shore Trust and Celeste J. Williams Lifetime QTIP Trust, Mr. McNulty has sole voting and dispositive power over
    the shares held by each trust, and as such, is deemed to have beneficial ownership (as determined under Section 13(d) of the
    Exchange Act) of the securities held by each trust. Mr. Jonnie R. Williams, Sr., our founder and the settlor of the Bay Shore Trust,
    does not have voting or dispositive power over the shares held by the Bay Shore Trust.

Item
13. Certain Relationships and Related Transactions, and Director Independence.

The
following is a description of transactions within the last three years to which we have been a party, in which the amount involved exceeded
or will exceed $120,000, and in which any of our executive officers, directors or holders of more than 5% of our voting securities, or
an immediate family member thereof, had or will have a direct or indirect material interest. We believe the terms obtained or consideration
that we paid or received